Lina Wirestam, Jesper Karlsson, Astrid Welin, Jhonatan Antonio Álvarez-Gómez, Jonas Wetterö, Christopher Sjöwall, Helena Enocsson
{"title":"干扰素α诱导的uPAR在单核细胞上的表达是SLE患者发生器官损伤高风险时可溶性uPAR增加的潜在来源。","authors":"Lina Wirestam, Jesper Karlsson, Astrid Welin, Jhonatan Antonio Álvarez-Gómez, Jonas Wetterö, Christopher Sjöwall, Helena Enocsson","doi":"10.1007/s10238-025-01897-4","DOIUrl":null,"url":null,"abstract":"<p><p>The soluble urokinase plasminogen activator receptor (suPAR) has been shown to adequately predict the risk of organ damage development in patients with systemic lupus erythematosus (SLE). However, the cellular source and mechanism of increased circulating levels remain unknown. The cell-bound uPAR is expressed on various cell types and can be shed from the plasma membrane surface by proteases, resulting in the soluble form, suPAR. Herein, leukocyte uPAR expression and plasma suPAR levels were explored in unstimulated and cytokine-treated (tumor necrosis factor; TNF or interferon-α; IFN-α) blood from patients with SLE (n = 37) and healthy blood donors (HBD; n = 27). Unstimulated or cytokine-treated whole blood was thereafter used for analysis of cellular uPAR expression by flow cytometry, and plasma suPAR levels by enzyme-linked immunosorbent assay (ELISA). Monocytes and neutrophils had the most prominent uPAR expression and showed increased expression after TNF addition to the blood (p < 0.001). Addition of IFN-α resulted in increased uPAR expression only in patients (p < 0.05). No differences in uPAR expression were found depending on organ damage or other clinical variables. Nevertheless, suPAR levels were higher in patients with organ damage (p < 0.01). Unstimulated suPAR levels were correlated with monocyte uPAR expression in patient samples (rho = 0.4). As circulating suPAR levels can predict organ damage development in SLE, it is important to unravel its potential disease mediating effects as well as cellular sources. Results of this study suggest IFN-α as a regulator of uPAR expression in SLE and monocyte uPAR as an important source of plasma suPAR.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"317"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540527/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interferon alpha-induced uPAR expression on monocytes as a potential source of increased soluble uPAR in patients with SLE at high risk of developing organ damage.\",\"authors\":\"Lina Wirestam, Jesper Karlsson, Astrid Welin, Jhonatan Antonio Álvarez-Gómez, Jonas Wetterö, Christopher Sjöwall, Helena Enocsson\",\"doi\":\"10.1007/s10238-025-01897-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The soluble urokinase plasminogen activator receptor (suPAR) has been shown to adequately predict the risk of organ damage development in patients with systemic lupus erythematosus (SLE). However, the cellular source and mechanism of increased circulating levels remain unknown. The cell-bound uPAR is expressed on various cell types and can be shed from the plasma membrane surface by proteases, resulting in the soluble form, suPAR. Herein, leukocyte uPAR expression and plasma suPAR levels were explored in unstimulated and cytokine-treated (tumor necrosis factor; TNF or interferon-α; IFN-α) blood from patients with SLE (n = 37) and healthy blood donors (HBD; n = 27). Unstimulated or cytokine-treated whole blood was thereafter used for analysis of cellular uPAR expression by flow cytometry, and plasma suPAR levels by enzyme-linked immunosorbent assay (ELISA). Monocytes and neutrophils had the most prominent uPAR expression and showed increased expression after TNF addition to the blood (p < 0.001). Addition of IFN-α resulted in increased uPAR expression only in patients (p < 0.05). No differences in uPAR expression were found depending on organ damage or other clinical variables. Nevertheless, suPAR levels were higher in patients with organ damage (p < 0.01). Unstimulated suPAR levels were correlated with monocyte uPAR expression in patient samples (rho = 0.4). As circulating suPAR levels can predict organ damage development in SLE, it is important to unravel its potential disease mediating effects as well as cellular sources. Results of this study suggest IFN-α as a regulator of uPAR expression in SLE and monocyte uPAR as an important source of plasma suPAR.</p>\",\"PeriodicalId\":10337,\"journal\":{\"name\":\"Clinical and Experimental Medicine\",\"volume\":\"25 1\",\"pages\":\"317\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540527/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10238-025-01897-4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-025-01897-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Interferon alpha-induced uPAR expression on monocytes as a potential source of increased soluble uPAR in patients with SLE at high risk of developing organ damage.
The soluble urokinase plasminogen activator receptor (suPAR) has been shown to adequately predict the risk of organ damage development in patients with systemic lupus erythematosus (SLE). However, the cellular source and mechanism of increased circulating levels remain unknown. The cell-bound uPAR is expressed on various cell types and can be shed from the plasma membrane surface by proteases, resulting in the soluble form, suPAR. Herein, leukocyte uPAR expression and plasma suPAR levels were explored in unstimulated and cytokine-treated (tumor necrosis factor; TNF or interferon-α; IFN-α) blood from patients with SLE (n = 37) and healthy blood donors (HBD; n = 27). Unstimulated or cytokine-treated whole blood was thereafter used for analysis of cellular uPAR expression by flow cytometry, and plasma suPAR levels by enzyme-linked immunosorbent assay (ELISA). Monocytes and neutrophils had the most prominent uPAR expression and showed increased expression after TNF addition to the blood (p < 0.001). Addition of IFN-α resulted in increased uPAR expression only in patients (p < 0.05). No differences in uPAR expression were found depending on organ damage or other clinical variables. Nevertheless, suPAR levels were higher in patients with organ damage (p < 0.01). Unstimulated suPAR levels were correlated with monocyte uPAR expression in patient samples (rho = 0.4). As circulating suPAR levels can predict organ damage development in SLE, it is important to unravel its potential disease mediating effects as well as cellular sources. Results of this study suggest IFN-α as a regulator of uPAR expression in SLE and monocyte uPAR as an important source of plasma suPAR.
期刊介绍:
Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.